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Purpose: We conducted a feasibility study to investigate the use of ketogenic diets (KDs) as an 
adjuvant therapy for patients with glioblastoma (GBM), investigating i) trial feasibility; ii) potential 
impacts of the trial on patients’ quality of life and health; iii) patients’ perspectives of their decision-
making when invited to participate in the trial and iv) recommending improvements to optimize 
future phase III trials.   
Methods: A single-center, prospective, randomized, pilot study (KEATING), with an embedded 
qualitative design.  Twelve newly diagnosed patients with GBM were randomized 1:1 to modified 
ketogenic diet (MKD) or medium chain triglyceride ketogenic diet (MCTKD).  Primary outcome was 
retention at three months.  Semi-structured interviews were conducted with a purposive sample of 
patients and caregivers (n=15).  Descriptive statistics were used for quantitative outcomes and 
qualitative data were analyzed thematically aided by NVivo.   
Results: KEATING achieved recruitment targets, but the recruitment rate was low (28.6%).  
Retention was poor; only four of 12 patients completed the three-month diet (MCTKD n=3; MKD 
n=1).  Participants’ decisions were intuitive and emotional; caregivers supported diet 
implementation and influenced the patients’ decision to participate.  Those who declined made a 
deliberative and considered decision factoring diet burden and quality of life.   A three-month diet 
was undesirable to patients who declined and withdrew.   
Conclusion: Recruitment to a KD trial for patients with GBM is possible.  A six-week intervention 
period is proposed for a phase III trial.  The role of caregivers should not be underestimated.  Future 
trials should optimize and adequately support the decision-making of patients.   
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Introduction 
Glioblastoma (GBM) is the commonest malignant primary brain tumor in adults, affecting 2-3 per 
100,000 per year (1).  Even with maximal safe resection, radiotherapy and temozolomide (2,3), the 
prognosis remains poor (4).  In the last 10 years, a series of large-scale clinical trials testing targeted 
therapies have all reported negative results (4-6) with no change in the current standard of care.  
Patients and caregivers often explore other alternative treatment options, including dietary changes 
such as the ketogenic diet (KD).  Indeed, the James Lind Alliance Priority Setting Partnership 
identified that ‘the effect of lifestyle factors, including diet, on tumor growth’ to be a top 10 research 
priority for the neuro-oncology community (5). 
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KD is an ‘umbrella term’ used to describe high fat, low carbohydrate, adequate protein diets which 
promote the utilization of fat for energy, in the form of ketones.  Initially hypothesized to work by 
exploiting the ‘Warburg effect’ (6–9), newer theories have proposed other mechanisms of action, 
with ketone bodies and medium chain triglyceride (MCT) fats playing a role in tumor metabolism, 
rather than or in addition to a reduction in glucose (10–13).  Animal models of glioma have shown 
that KD potentiates the effects of radiotherapy (14), reduce peri-tumoral edema (15) and reduce 
tumor angiogenesis (7).  In patients with gliomas, the evidence for KD is limited to case studies and 
single case reports (16–22); all utilizing different KDs at different time points in the treatment 
pathway.  No studies have been powered to assess efficacy.  
 
Prior to designing and undertaking an adequately powered randomized control trial (RCT) 
investigating the efficacy of KDs in the therapeutic management of GBM, feasibility must be 
demonstrated (23–25).  We conducted the KEATING study to i) investigate protocol feasibility; ii) 
explore the potential impact of the study on patients’ quality of life and health; iii) explore patients’ 
perspectives of their decision-making when invited to participate in the study; and iv) optimize 




KEATING consisted of two parts; a pilot study and a qualitative study.  To investigate the feasibility of 
KDs as an adjuvant therapy for patients with newly diagnosed GBM undergoing chemoradiotherapy 
a prospective, non-blinded, single-center, randomized pilot study was undertaken.  Twelve patients 
were randomized in a 1:1 ration to either medium chain triglyceride ketogenic diet (MCTKD) or 
modified ketogenic diet (MKD).  A three-month dietary intervention was planned (primary end 
point), following which patients could choose to continue with the diet for a total of 12 months 
(secondary end point).  To explore the decision-making of patients’ invited to participate in KEATING 
a qualitative study was embedded, interviewing patients who participated and declined, along with 
their caregivers.  Ethical approval was granted by North West-Greater Manchester West Research 
Ethics Committee (17/NW/0013).  KEATING was registered with the International Standard 
Randomized Controlled Trial Number Registry (reference number 71665562) and ClinicalTrials.gov 
(reference number NCT03075514).  The KEATING pilot study protocol has been published previously 




Patients were recruited from a single adult neuroscience center. Patients were eligible if they were 
≥16 years, ECOG performance status 0-2, had histologic diagnosis of GBM (WHO grade IV (27) within 
last four months (biopsy of surgical resection), were planned to undergo radiotherapy and 
temozolomide chemotherapy (2).  Patients were not eligible if they had any prior use of a KD, 
kidney, liver or gallbladder dysfunction, Metabolic or eating disorder, Body mass index (BMI) 
≤18.5kg/m2, were taking weight loss medications, pregnant or breastfeeding, or had Medical 
conditions that may increase risks associated with KD. 
Randomization 
Patients were randomized to either MCT KD or MKD using 'sealedenvelope'™ randomization system 
and a permuted block randomization method, ensuring similar numbers in each group, at a ratio of 
1:1.  This was constructed and administered by the study statistician (CTS), who was not involved 
with recruiting patients, thus concealing the sequence of allocation.  Patients were then informed of 
their dietary intervention group by telephone and initiated diet within five working days of consent.     
Dietary Intervention and Procedures 
Two KDs were included in KEATING; MCTKD and MKD.  A comparison of the macronutrient content, 
example meal plan and monitoring requirements for each diet can be found in online resource 1, 
table A.  Patients and their caregiver (if present) received dietary education from the dietician and 
were provided with a bespoke seven-day meal plan, recipes, dietary information sheets and food 
diaries.  MCT was provided as Betaquik® (Vitaflo International Ltd), a nutritional product available by 
prescription.  Patients were reviewed by telephone at weeks one, three and nine, and in an 
outpatient’s clinic at weeks six and twelve.  Patients who wished to continue with the diet were then 
reviewed at six, nine and 12 months.  Urinary ketones were monitored twice daily for the first six 
weeks, then weekly thereafter using Ketostix® (Bayer, Germany).  Blood ketones and glucose levels 
were monitored once weekly using GlucoMen Aero 2K® home monitoring kit (Abbott Laboratories, 
UK). All surgical and oncological interventions were undertaken as per current standard of care (28).   
Outcomes 
The primary outcome for KEATING was to estimate retention rate at three months to inform sample 
size calculations for future definitive trials.  Secondary outcomes included estimations of recruitment 
rates, enrolment rates, long term retention rates and to obtain data on dietary compliance through 
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food diaries, ketosis through ketone diaries, dietetic time to complete intervention, protocol 
refinements, completeness of data, quality of life assessed using EORTC QLQ C30 and BN20 
questionnaires, food acceptability assessed through questionnaire, gastrointestinal side effects 
graded using Common Terminology Criteria for Adverse Event (CTCAE) reporting, biochemical 
markers (renal, bone, liver function tests, fasting lipid and fasting glucose) and anthropometry 
(weight, BMI, hand grip strength, mid arm muscle circumference, free fat mass and waist 
circumference.  All outcomes were assessed at three months and twelve months.    
 
Pilot success for KEATING was graded using a predetermined traffic light system (≥75% to proceed, 
≥50% required review and <50% study closure), which considered recruitment success, retention 
rates, dietary acceptability, the commencement of diet pre chemoradiotherapy and extent of 
missing data (29).  Magnetic Resonance Imaging (MRI) was used to interpret tumor progression. 
Progression free survival (PFS) was defined as the time from date of surgery randomization to date 
of recurrence on MRI.  Recurrence was defined by a Neuroradiologist using the Response 
Assessment in Neuro-Oncology (RANO) criteria (30).  Overall survival (OS) was defined as the time 
from date of surgery to date of death from any cause. Adverse events (AE) and serious adverse 




Previous feasibility work estimated recruitment targets of one patient per month (32), in keeping 
with National Institute for Health Research (NIHR) funded trials (33).  Twelve patients were to be 
recruited over 12 months. Descriptive statistical methods were used and PFS and OS were PFS and 
OS were assessed Kaplan-Meier survival curves.  During the course of the pilot study it was clear that 
retention on diet was an issue and with agreement from the Trial Steering Committee, a sub 
analyses was introduced at week six, with a view to providing further information which would 
inform the design of later trials.  This was not included in the original study protocol (for 
amendments see online resource 2).  
Qualitative study  
Due to poor recruitment in the early stages of the KEATING study, we proceeded to amend the 
protocol to embed a qualitative component to explore patients’ decision-making about KEATING.  
Participants for the qualitative study were a purposively sampled sub-set of patients and their 
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caregivers, who had been approached to participate in KEATING (34,35).  Sampling was informed by 
the review of screening logs maintained as part of KEATING and aimed to include both those who 
consented and declined, those randomized to MCTKD and those to MKD.  Patients were interviewed 
retrospectively, up to three months after being approached about KEATING.  Adequate sample size 
was determined using the ‘information power’ concept (36,37).  The interviews were conversational, 
patient-centered, topic guided (see online resource 3, table A) and iterative.  The topic guide was 
devised by two members of the research team (KM, GC).  The researcher conducting the interviews 
had a dual role (dietician and qualitative researcher), therefore, interviews were reflexive and 
conducted in a gentle, sensitive and non-judging manner, to make the experience as comfortable as 
possible for patients.  Interviews were audio-recorded and transcribed.  Analysis drew on the Braun 
and Clarke thematic approach to identify patterns of meaning within the data (38).  KM lead a 
process of iterating between the developing analysis and new data (familiarization).  Other members 
of the qualitative study team (BY and GC) read a sub-set of transcripts and developed the analysis by 
periodic discussion.  Integration between KEATING and the embedded qualitative study took place 
after individual analysis had occurred.  Integration was conducted by three authors (KM, GC, BY).     
Results 
KEATING participant characteristics  
Between 1st April 2017 and 8th February 2018 we assessed 57 patients for eligibility.  Fifteen were 
ineligible (26.3%), 30 declined (52.6%) and 12 (21.1%) were randomized.  Of those recruited eight 
were male and four female, with a median age of 57 years (44 – 66 years). Figure 1 shows the 
patient flow through the study and table 1 presents the demographic and clinical characteristics of 




Figure 1: CONSORT diagram for KEATING 
  Assessed for eligibility (n=57) 
Randomized (n=12) 
Excluded (n=15) 
• PS>2 (n=4) 
• BMI<18.5 (n=2) 
• Liver dysfunction (n=1) 
• No STUPP (n=2) 
• Gallbladder dysfunction (n=2) 
• T2DM requiring medications 
(n=1) 
• Kidney dysfunction (n=1) 
MKD (n=6) MCTKD (n=6) 
Withdrew (n=4) 
• Dietary burden 
(n=2) 
• Tumour progression 
(n=1) 
• Nausea (n=1) 
Withdrew (n=2) 
• Dietary burden (n=1) 
• Recruited to another 
trial (n=1) 
Complete 12 weeks (n=3) Completed 12 weeks (n=1) 
Withdrew (n=1) 
• GI intolerance (n=1) 
Completed 12 months (n=2) Completed 12 months (n=1) 
Withdrew prior to 
commencing diet (n=1) 
• Non related SAE  (n=1) 
Withdrew prior to 
commencing diet (n=1) 
• Changed mind (n=1) 
 
Commenced MCTKD (n=5) Commenced MKD (n=5) 
Declined participation (n=30) 
• Declined research 
involvement (n=12) 
• No contact (n=7) 
• Burden of visits (n=6) 
• Dietary burden (n=3) 
• Study funder (n=1) 





















MGMT IDH-1 ATRX 
T01 Male 53 Right temporal GTR, RT, TMZ Unmethylated Wildtype Retained 5 
(2-4) 
MCTKD 22.4 32.4 35.4 
T13 Male 49 Left parietal NTR, RTX, TMZ Unmethylated Wildtype Retained 4 
(0) 
MCTKD 5.1 14.4 60.6 
T23 Female 54 Left frontal NTR, RTX, TMZ Unmethylated Wildtype Retained 4 
(0) 
MCTKD 5.7 44.4 83.6 
T27 Female 62 Right occipital GTR, RTX, TMZb Methylated Wildtype Retained 2 
(0) 
MKD 0 5.1 NRe 
T28 Male 64 Left temporal Bx, RTX, TMZa Unmethylated Wildtype Retained 4 
(3-4) 
MKD 7 13.1 67.3 
 
T39 Female 66 Right parietal NTR, RTX, TMZ Methylated Wildtype Retained 4 
(0) 
MKD 5.3 64.3 NRe 
T44 Male 44 Right temporal GTR, RTX, TMZ Methylated Mutant Mutated NA 
 
MKD 52 NAd NRe 
T45 Male 46 Left frontal NTR, RTX, TMZ, 
Lomustine 
Unmethylated Wildtype Retained 3 
(2-3) 
MCTKD 52 14.0 NRe 
T47 Female 58 Right frontal NTR, RTX, TMZa Inconclusivec Wildtype Retained 2 
(0) 
MKD 4.6 14.0 31.6 
 
T51 Male 57 Left frontal STR, RTX, TMZ Methylated Mutant Mutated 1 
(1-1.5) 
MCTKD 52 NAd NRe 
T52 Male 60 Left frontal NTR, RTX, TMZa Unmethylated Wildtype Retained 2 
(0) 
MCTKD 0 23.9 NRe 
T57 Male 57 Right multifocal Bx, RTX, TMZa Unmethylated Wildtype Retained 2 
(0) 
MKD 6 14.0 57.1 
Abbreviations: ATRX = alpha thalassemia/mental retardation syndrome X linked; Bx = biopsy; DEX = dexamethasone; GTR = gross total resection; MCT KD = medium chain triglyceride ketogenic diet; MGMT = O6-methylguanine-DNA 
methyltransferase; MKD = modified ketogenic diet; NA = not applicable; ND = no data recorded by patient; NR = not reached; NTR = near total resection; OS = overall survival; PFS = progression free survival; RTX = radiotherapy; SD = 
standard deviation; STR = subtotal resection; TMZ = temozolomide; Treatment = treatment received whilst following a ketogenic diet; a = unknown if completed full course of radiotherapy and chemotherapy as withdrew from study; b 
= 6 days of temozolomide not given; c= insufficient tissue to perform MGMT analysis; d= no progression at time of reporting (08/MAR/2019); e= alive at time of reporting (08/MAR/2019). 
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Primary outcome: Retention at three months 
Of the 12 patients randomized in KEATING (n=6 MCTKD; n=6 MKD), two withdrew prior to 
commencing the diet (n=1 MCTKD; n=1 MKD).  Reasons for withdrawal were non-dietary related SAE 
(n=1) and patient change of mind (n=1).  Of the 10 patients who commenced diet, six withdrew 
before reaching the three month primary end point (n=2 MCTKD; n=4 MKD).  The median duration 
until discontinuing the MCTKD was 38 days (36-40 days; n=2) and for MKD was 39.5 days (32-49 
days; n=4).   
Secondary outcomes: Protocol feasibility  
Recruitment  
Twelve patients were recruited over 12 months from a sample of 42 eligible patients, achieving a 
recruitment rate of 28.6% (or 21% of the overall screened population).   
Long term retention 
Of the 12 patients randomized in KEATING, four continued with their KD after month three (n=3 
MCTKD; n=1 MKD).  One patient (MCTKD group) then stopped at month six due to gastrointestinal 
side effects.  In total, three patients completed the 12 month intervention period (n=2 MCTKD; n=1 
MKD).  These patients all chose to continue with their KD after completing the study.   
Level of ketosis 
During the first six weeks, 79.7% of MCTKD (n=3) and 79.3% of MKD (N=3) recordings were within the 
desired level of ≥4mmol/L.  Those who withdrew from the study reported lower urinary and serum 
ketone levels than those who stayed on diet up to month 12.  The median level of urinary ketosis for 
each patient for their duration on diet is shown in online resource 3, figure A.   
 
Secondary outcomes: Impact of the study on patients’ health 
Quality of life 
At baseline, there was little difference between the Global Health Status (GHS) of those patients 
who went on to withdraw and those who continued with their diet and were retained within the 
study, in either dietary group (withdrew MCTKD 72.2±20.7 [n=3]; retained MCTKD 75±6.8 [n=3]; 




The GHS of those who withdrew from the study at week six, fell below the brain cancer reference 
value in both the MCTKD and MKD groups (withdrew MCTKD 41.7±0 [n=1]; withdrew MKD 50±0 
[n=2]).  For those who continued with their diet and were retained within KEATING, GHS improved 
for the patient following MKD and reduced for those patients following MCTKD.  In both groups the 
GHS remained above the brain cancer reference value (retained MCTKD week six 66.7±0 [n=3]; 
retained MCTKD month three 66.7±13.6 [n=3]; retained MCTKD month 12 66.7±8.4 [n=2]; retained 
MKD 100±0 [n=1] from week six onwards) (see online resource 3, figure B). 
 
Food acceptability  
Food acceptability reduced from baseline in both groups.  The lowest food acceptability scores were 
recorded at week six of following the diet (baseline MCTKD 60.7±10.5 [n=6]; baseline MKD 54.3±6.2 
[n=6]; week six MCTKD 42±8.9 [n=4]; week six MKD 43.5±12.8 [n=4]).  Food acceptability then 
improved between week six and three months (MCTKD 49±2.9 [n=3]; MKD 58 [n=1]), but reduced 
slightly before the end of the study (MCTKD 47.5±6.5 [n=2]; MKD 53 [n=1]).   
 
Adverse and serious adverse events 
There were five adverse events and three serious adverse events.  Adverse events were due to 
hypokalemia (n=2, CTCAE grade 1), hypernatremia (n=1, CTCAE grade 1), hypocalcaemia (n=1, not 
classified as adjusted calcium >2mmol/L) and a partial seizure (n=1, CTCAE 1).  Serious adverse 
events were due to post-operative wound infection (n=1, CTCAE grade 3, resulting in withdrawal 
from the assigned dietary intervention), seizure (n=1, CTCAE grade 2) and back pain (n=1, CTCAE 
grade 2), none of which were related to the dietary intervention.  
 
Survival analysis      
The median time to progression was 14.4 weeks (SE 14.6; 95% CI 0-42.9 weeks).  Median overall 
survival was 67.3 weeks (SE 6.2; 95% CI 55-79.6 weeks).  Survival analysis is illustrated in figure 2.    
Additional outcomes 
Additional outcome reporting as per the KEATING protocol can be located in online resource 3 for 
the following outcomes: enrolment of participants prior to, during and post chemoradiotherapy 
commencement; dietary compliance; dietary adjustments required to achieve ketosis; dietetic time 
required for dietary interventions; gastrointestinal side effects; changes to biomarkers;  
anthropometric changes; and determining pilot success.     
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Figure 2: Progression free and overall survival of patients who commenced diet (MCT KD n=5; MKD n=5)
 
NB: Data censored on 08/MAR/2019 for patients who had not progressed.   NB: Data censored on 08/MAR/2019 for patients who were alive at time of reporting.  
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Qualitative study  
Participant characteristics 
Fifteen patients and their caregivers were invited to be interviewed.  Between January and April 
2018, 10 patients and five of their caregivers, all of whom were white British, were interviewed 
(table 2).  All participants were interviewed separately except one patient and one relative who were 
interviewed jointly.  Individual interviews lasted for an average (median) of 44 minutes (36 - 62 




Abbreviations: IMD = Index of Multiple Deprivation; MCT KD= medium chain triglyceride ketogenic diet; MKD= modified ketogenic diet.  
Key: Continued participation = continued with the intervention beyond three months; Early withdrawal = withdrew from KEATING following consent and randomization, but prior to 
commencing a KD; Delayed withdrawal = withdrew from KEATING after commencing KD but before the primary end point of three months; Declined = declined to participate in 
KEATING.  Time to interview = time from initial contact about KEATING to qualitative interview. *Index of Multiple Deprivation (England): decile of 1 = 10% most deprived areas of 
England, decile of 10 = 10% least deprived areas of England; Ɨ Index of Multiple Deprivation (Wales): 10% = 10% most deprived areas of Wales, >50% = >50% least deprived areas of 
Wales.   

















T27 Female 60-69 1* MKD 
 
Early withdrawal No - - - 
T30 Female 70-79 >50%Ɨ - 
 
Declined Yes T30/R Male Husband 
T35 Female 50-59 4* - 
 
Declined No - - - 
T39 Female 60-69 30-50%Ɨ MKD 
 
Delayed withdrawal Yes T39/R Male Husband 
T44 Male 40-49 2* MKD 
 
Continued participation No - - - 
T45 Male 40-49 7* MCTKD 
 
Continued participation Yes T45/R Female Wife 
T47 Female 60-69 2* MKD 
 
Delayed withdrawal Yes T47/R Male Husband 
T51 Male 50-59 10* MCTKD 
 
Continued participation Yes T51/R Female Wife 
T52 Male 60-69 2* MCTKD 
 
Early withdrawal No - - - 
T55 Male 60-69 8* - 
 
Declined No - - - 
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Integrated results of KEATING and the embedded qualitative study 
Table 3 integrates the findings of the KEATING and the embedded qualitative study, using an 
adapted triangulation protocol (39).  Throughout the table, we present patients’ verbatim quotes in 
speech marks, with ellipses indicating missing text and square brackets indicating replacement or 
explanatory text.  To preserve anonymity, all patients are identified by the patient’s KEATING study 
screening log number (e.g. T01) and caregivers by an associated number (e.g. T01/R).  We 
highlighted if the results of the two studies converge, are complementary, are contradiction, or are 
silent (39).  Further detailed analysis of the qualitative study can be found via online resource 4. 
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Table 3: Integrated findings of KEATING and the embedded qualitative study  
Theme KEATING pilot study  Qualitative study Convergence, 
complementary, 
contradiction, silence  
1. Recruitment Recruitment rate of 
28.6% 
For those patients who participated in KEATING their decision was 
intuitive and emotional: “I jumped in, you know, took the opportunity 
with both hands … it was a no brainer” (T44) and “more of a gut 
decision” (T52).  Participating offered them the opportunity to “take 
control” and “fight for their life” (T44).   
 
For those who declined, the decision was deliberative and considered, 
consistently describing a lack of perceived personal benefit from 
participation: “the only thing I think about this study is what would 
benefit me” (T35). One viewed KEATING as “a waste of your life” (T35).  
 
Both groups validated their decision, seeking approval from their 
caregiver: “it was a case of speaking to my family and getting their 
support to make sure that they were on board with what I was going to 
do, my family gave me the thumbs [up]” (T44) and some patients spoke 
of discussing their decision to participate with their relative, sharing the 
decision: “we had a discussion together as to whether or not we felt it 
was the right thing for me to do… [caregiver] just supported me with it, 
he felt that I should be giving it a go as well” (T47). 
 
Complementary. 
Findings from the 
qualitative research 
explain why some 
patients participated in 
KEATING, whilst others 
declined.   
2. Retention 33% retention rate at 3 
months (MCT KD n=3; 
MKD n=1)  
 
25% retention rate at 12 
months (MCT KD n=2; 
MKD n=1) 
 
Those who continued to participate in KEATING spoke positively about 
the diet and related retention to support from their caregiver.  
Caregivers were supportive and emphasized the diet to be “a new 
normal for us” (T45/R).  
 
Patients validated their decision to continue on a regular basis making 
reference to the influence of ‘positive stories’ from long term 
ketogenic-glioblastoma survivors: “there's lot of good results of people 
having positive responses to it [ketogenic diet]… the one story was the 
Complementary.  
Findings from the 
qualitative research 
identifies why some 
patients withdrew from 
KEATING.  The 





Median duration until 
discontinuing the MCT KD 
was 38 days (36-40 days; 
n=2) and for MKD was 
39.5 days (32-49 days; 
n=4) 
guy who had a, erm had the same tumor, he’s on this [ketogenic diet], 
his [tumor] reduced, what's not to want to go for that?” (T45).  They 
also found motivation from external sources such as “clear scans” (T44), 
with ketones providing “a quick confidence check and every now and 
again” (T45).  
 
Those who withdrew, spoke of negative experiences which reduced 
their quality of life: “I was worrying, I was waking up, I was literally 
waking up… and that’s all I could think about: ‘Oh I've got to get my fats 
intake today’. And it was pulling me down” (T39).  They also reported 
finding low ketones ‘demoralizing’.  
continuing to 
participate in KEATING.  
3. Role of 
caregivers 
No data  The caregivers of those patients who participated in KEATING also 
described their decision as instantaneous, “I’d take anything with open 
arms because anything that would help cure [the tumor], you know… I’d 
jump at it” (T47/R), with caregivers attributing a kind of selfishness to 
their motives: “I wanted her to have a go… I suppose it’s a bit selfish 
really but you know you, there’s a selfish element in it because you want 
her to be here sort of thing” (T39/R). 
 
For patients who declined, caregivers generally agreed with the 
patients’ decision in relation to quality of life: “well I think it’s 
something to be worthwhile but, erm, I was a bit concerned that it was 
a very restrictive diet for my wife to take at this stage really” (T35/R). 
 
In relation to retention, patients also reported caregivers to have an 
important role.  Those who participated in KEATING required support 
both practically and emotionally, with caregivers emphasizing the diet 
to be “a new normal for us” (T45/R).  Whilst those who withdrew 
sought their relative opinion and support in their decision to withdraw: 
“it’s too long on the diet” (T47/R). 
Silence in KEATING, 
whilst the qualitative 
study offered insight 
into the role of the 
caregiver in the 
decision-making process 
and in supporting the 
patient to implement 
the intervention.  
4. Quality of 
life 
Reduced from baseline   Those who initially consented to participate in KEATING and later 
withdrew reported the diet to have a negative impact on their quality 






that’s all I could think about: ‘Oh I've got to get my fats intake today’. 
And it was pulling me down” (T39).   
 
Whilst those who continued to participated reported the diet to offer 
“a great quality of life with cancer” (T44). 
 
Those who declined to participate considered the impact of the diet on 
their quality of life as part of their decision-making: “You get to around 
70 years old and that’s where I am. So now every day I get up I want a 
quality day…and so having a complex regime around diet again it 
doesn’t appeal” (T55), with one viewing the KEATING as “a waste of 
your life” (T35).  
information about 
patients’ perceptions of 
the importance of 
quality of life, over the 
course of the study, and 
how this impacted their 
decision to retain or 
withdraw.    
5. Dietary 
acceptability 
Reduced from baseline  For those who declined to participate and those with withdrew, a three 
month dietary intervention was considered to be ‘too long’ and 
unsustainable to “live with that forever more” (T47), but reflected that 
they might have considered participating in KEATING for “half of the 
time” (T35).   
Complementary.  
Dietary acceptability 
reduced from baseline 
in all but one patient 
(MKD).  The qualitative 
study enhanced 
researcher 
understanding of a 
realistic and acceptable 
timeframe for the 
dietary intervention.     
Definitions: Convergence = Uniformity within the quantitative and qualitative findings; Complementary = Quantitative and qualitative results enhance the qualities 




This randomized, pilot study with an embedded qualitative design was designed to explore the 
feasibility of KD trials for patients with glioblastoma, with a view to recommending improvements to 
optimize the design of future phase III trials.   
 
KEATING recruited to time and target, despite an initial slow start.  The recruitment rate (28.6% of 
the eligible population) was much lower than NIHR HTA funded oncology clinical trials (50 to 89%) 
(33), but in keeping with recent survey data from the National Brain Tumour Society, with 21% of 
patients with brain tumors participating in clinical trials (40,41).  Screening log data at the start of 
KEATING revealed that patients were declining to participate due to i) not wanting to participate in 
research; ii) the burden of dietitian visits; and iii) the burden of KD.  During the qualitative study 
those patients who declined to participate in KEATING identified their quality of life as an important 
factor in decision-making, and this aspect was not detected in the screening log data or in previous 
surveys regarding participation barriers (40).  These patients also spoke of the role of caregivers in 
influencing their decision to participate or not in KEATING, an aspect highlighted in trials elsewhere 
(41).  In contrast, patients who consented to KEATING made an intuitive and emotional decision, 
later reflecting that this decision was based upon quantity rather than quality of life. This optimism 
surrounding longevity of life is often used as a coping strategy by patients and may not invalidate 
their informed consent.  There is currently little guidance offered by the Health Research Authority 
(HRA) Good Clinical Practice guidelines (42) regarding this matter, thus clinicians should continue to 
use their clinical judgement when assessing patients’ informed consent to participate in trials.  Our 
findings are in keeping with recent publications highlighting the need for improved recruitment 
strategies and decisional support in neuro-oncology populations (40,41).     
 
The retention rate in KEATING was lower than anticipated.  Out of the 12 patients randomized, 10 
commenced KD and only four met the primary endpoint of three-month dietary intervention (1 KD, 
3 MKD).  Cancer trials in general report median retention rates of 89% (IQR 79-97% with valid 
primary outcome data at follow up) (33) and previous KD studies for patients with GBM report 
retention rates of 50 to 100%, with retention determined at eight weeks (19), three months (18,32) 
and the point of tumor progression (17).  However, patients in these previous KD studies self-
selected to try the diet, mainly at recurrence or post-treatment, creating an optimistic bias in 
retention, when compared to the general unselected GBM population approached for KEATING.  
Those who withdrew from KEATING did so either after randomization but prior to commencing the 
diet (n=2) or after following the KD for approximately six weeks (MCTKD median 38 days [36 to 40 
19 
 
days], n=2); MKD 39.5 days [32 to 49 days], n=4), during which time patients were undergoing 
radiotherapy and concomitant temozolomide chemotherapy.  Patients reported their reasons for 
withdrawal to be related to dietary burden and side effects, in particular nausea, which could have 
been related to the chemotherapy.  Those continued on their assigned KD were generally younger 
patients with more favorable prognostic features (MGMT methylated; IDH-1 mutant) and this may 
also have influenced their ability to stay on the study and implement the diet. 
 
The reasons for poor retention on diet were explored in our qualitative study.  Those who withdrew 
spoke of finding their low urinary and blood ketones to be ‘demoralizing’, feeling that the diet was 
not working, and withdrawing due to the negative effect this feeling had on their quality of life.  This 
was confirmed in the quality of life data as patients who withdrew reported their global health 
status (GHS) to be below the brain cancer reference value at week six of the study.  We appreciate 
multiple factors can affect the quality of life for these patients and whilst ketones are used to 
monitor the diet, urinary ketones not always robust markers of compliance and can be effected by 
hydration levels and the use of dexamethasone.  Therefore low ketones may demoralize patients, 
even when they appear to be following the diet robustly.   
 
For those patients who continued to participate in the trial to 12 months, GHS reduced within the 
MCTKD group and improved in the MKD group.  However, during the qualitative interviews, both 
groups reported to experiencing a ‘fantastic quality of life’ describing the diet as offering a sense of 
‘control’ whilst receiving their tumor treatment.  Although the EORTC QLQC30 and BN20 
questionnaires are validated for patients with glioblastoma, they are time consuming to complete 
and some questions are not relevant for patients following KDs.  It may be beneficial for future KD 
trials to reduce the length of the questionnaire and therefore patient burden, focusing particularly 
on GHS, as these questions provided the most insight in KEATING.   
 
During interviews, patients reported several motivational factors for continuing with the diet, 
including through online blogs of long term glioblastoma survivors, positive MRI results and high 
ketone levels, using these as a means of validating their decision to stay on diet.  This corroborates 
the findings from KEATING since high ketones indicted compliance with KD.  Patients with higher 
ketones stayed in the study, whilst those with lower ketones withdrew early, at around week six.  
Furthermore, a pilot study for KD in patients with other advanced cancers (breast, ovarian, lung, 
gastrointestinal), also experienced similar retention rates to KEATING (retention rate 31%, n=5 of 
20 
 
16), in a trial which permitted a more liberal KD (70g of carbohydrates per day) and where all food 
provision was provided (43).  Thus, a more flexible dietary approach may not be the simple solution.    
 
The high withdrawal rates in KEATING suggest that a three-month KD intervention may be too long 
for most patients.  Our qualitative study also highlighted that those who withdrew considered the 
three-month intervention to be undesirable, an opinion also reflected by those who declined, 
further corroborating findings from KEATING.  A shorter, six-week intervention, is likely to be more 
tolerable and acceptable to patients.  This could be offered alongside radiotherapy and concomitant 
chemotherapy, which coincides with the proposed optimal time for the diet derived from animal 
model data (14).  Offering the diet at the same hospital site as the radiotherapy would aid a timely 
start of the diet.  Whilst patients reported ‘feeling free again’ once the diet was discontinued, it is 
important to note, that this may not necessarily equate to dietary acceptability outside of a clinical 
trial.  In a future post-trial environment, information regarding the efficacy of the diet may be 
available, which could alter patients’ willingness to engage.    
 
The qualitative study also highlighted caregivers to be key in supporting patients to implement the 
diet.  The role of caregivers, both in the decision-making of patients and the ongoing support 
offered, were aspects that were underappreciated in KEATING.  A recent KD study for patients with 
Alzheimer’s disease, also highlighted dietary and caregiver burden to be influential over patient 
withdrawal (44).   
 
KEATING had several limitations.  The return rate of food and ketone diaries was low at 12 months, 
subsequently affecting the analysis.  This is a common problem in dietary intervention trials, given 
the time commitment required to return diaries.  All accounts of dietary intake were also self-
reported and at risk of reporter bias.  The sample size for the qualitative was small and we cannot be 
certain that saturation was achieved. Nevertheless, drawing on the concept of ‘information power’ 
in qualitative research (36), this study had a well specified aim, and it has provided insights that will 
be valuable in informing a future phase III trial.  Some patients were also interviewed up to three 
months after their decision about KEATING. They may have found it difficult to accurately recall their 
decision-making process, particularly given the nature of their condition and the numerous other 
decisions they will likely have had to make regarding their care and treatment. 
 




• To assess effectiveness in a phase III trial a six–week diet intervention period would be 
deliverable.   
• To optimize recruitment and retention a longitudinal, prospective, qualitative study, which 
focuses on patient and caregivers understanding and decision-making in the context of trial 
participation should be embedded within KD trials.  
• Future phase III trials would benefit from an internal pilot to further test the 
recommendations derived from KEATING, focusing on stop/ go criteria for staged 
recruitment, retention at six-weeks and commencement of diet prior to chemoradiotherapy.    
In conclusion, recruitment of patients with GBM to a KD trial is possible.  To assess efficacy in a 
phase III clinical trial, a six-week intervention period is proposed.  The role of caregivers in the 
patients’ decision-making process and in supporting patients to implement KDs should not be 
underestimated.   
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